MC
PTCT icon

Middleton & Co’s PTC Therapeutics PTCT Stock Holding History

Middleton & Co’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-17,640
Closed -$192K – 158
2016
Q4 		$192K Sell
17,640
-24,480
-58% -$257K 0.04% 154
2016
Q3 		$590K Buy
42,120
+2,170
+5% +$17.6K 0.13% 117
2016
Q2 		$280K Sell
39,950
-220
-0.5% -$1.61K 0.06% 136
2016
Q1 		$259K Buy
40,170
+550
+1% +$9.55K 0.06% 140
2015
Q4 		$1.28M Buy
39,620
+1,035
+3% +$30.5K 0.29% 71
2015
Q3 		$1.03M Buy
38,585
+17,775
+85% +$760K 0.24% 81
2015
Q2 		$1M Buy
20,810
+10,930
+111% +$638K 0.22% 86
2015
Q1 		$601K Buy
+9,880
New +$603K 0.13% 112

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Middleton & Co's PTCT Position: Q1 2017 in Review

Middleton & Co sold out of PTC Therapeutics (PTCT) in Q1 2017, closing a stake of 17,640 shares — an estimated $192K sold.

Middleton & Co first reported a position in PTCT in Q1 2015 and held it in 8 quarters. The position peaked at $1.28M in Q4 2015. 115 funds tracked by Wall St. Rank hold PTCT as of Q1 2017.

  • Middleton & Co reported no remaining PTC Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Middleton & Co sold 17,640 PTC Therapeutics shares in Q1 2017, an estimated $192K.
  • Middleton & Co first reported a position in PTC Therapeutics in Q1 2015 and held it in 8 quarters.
  • Middleton & Co's PTC Therapeutics position peaked at $1.28M in Q4 2015.
  • 115 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2017.

Based on Middleton & Co's 13F filing for Q1 2017, filed 19 Apr 2017.